TECVAYLI (Teclistamab) Everything You Need to Know

Поділитися
Вставка
  • Опубліковано 18 лис 2024

КОМЕНТАРІ • 5

  • @HTUMyeloma
    @HTUMyeloma  7 місяців тому

    On February 20, 2024 the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application for TECVAYLI® (teclistamab) for a reduced dosing frequency of 1.5 mg/kg every two weeks in patients with relapsed or refractory multiple myeloma who have achieved and maintained a complete response or better for a minimum of six months.There is a continued unmet need for patients with multiple myeloma and this approval allows increased flexibility in dosing schedule for appropriate patients with a weight-based regimen.

  • @emmanuelking9988
    @emmanuelking9988 5 місяців тому +1

    I'll try this treatment next month, so this video answered a lot of my questions. It was very helpful, thank you.

  • @markgray7733
    @markgray7733 11 місяців тому +1

    Great presentation. Thanks

  • @frankvitucci5677
    @frankvitucci5677 4 місяці тому +1

    Worst advice to give was to keep up on Covid vaccines

  • @SuperElwira
    @SuperElwira 6 місяців тому +1

    Why you wanted to isolate T-cells? To GMO production or organs? What is truth reason? Karyopharm and Amgen? Ot looks like very far from treatment. Why you can't treat HIV? Acyklovir does not work?